Table 1 Baseline characteristics
From: Cutaneous allodynia as predictor for treatment response in chronic migraine: a cohort study
Variable | Allodynia (n = 129) | No allodynia (n = 44) | P-value |
|---|---|---|---|
Female | 110 (85.3%) | 22 (50.0%) | < 0.001 |
Age (years) | 44.3 ± 10.5 | 47.3 ± 11.2 | 0.120 |
Age at onset | 17.4 ± 9.5 | 17.7 ± 9.2 | 0.858 |
Monthly Migraine days (MMD) | 14.9 ± 5.3 | 15.9 ± 6.1 | 0.311 |
Monthly Headache days (MHD) | 21.5 ± 4.7 | 21.1 ± 5.0 | 0.661 |
Days with use of acute headache medicationa | 16.1 ± 5.4 | 17.1 ± 6.0 | 0.306 |
Days with use of triptans | 11.1 ± 5.7 | 12.0 ± 7.5 | 0.391 |
Prophylactic treatment b | |||
Current use | 50 (38.8%) | 13 (29.5%) | 0.273 |
History of use | 115 (89.1%) | 43 (97.7%) | 0.081 |
BTA injections prior withdrawal | 61 (47.2%) | 26 (59.1%) | 0.222 |
Depression, % present (HADS-D ≥ 8) | 51 (39.5%) | 15 (34.1%) | 0.521 |
Anxiety, % present (HADS-A ≥ 8) | 50 (38.8%) | 5 (11.4%) | 0.001 |